OncoMatch/Clinical Trials/NCT04790305
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
Is NCT04790305 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Huaier Granule for carcinoma breast.
Treatment: Huaier Granule — This is a prospective, multicenter, randomized, parallel controlled, open-label study. The primary purpose of this study is to evaluate the efficacy of Huaier Granule on postoperative adjuvant therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety of long-term use of Huaier granules as postoperative adjuvant treatment of high-risk early-stage triple-negative invasive ductal carcinoma, and the changes of quality of life score after treatment with Huaier granule.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: neoadjuvant chemotherapy — neoadjuvant
neoadjuvant chemotherapy completed at least four cycles
Lab requirements
Blood counts
neutrophil count ≥ 1.5*10^9 / L, platelet count ≥ 100*10^9 / L, hemoglobin concentration ≥ 90 g / L (without transfusion)
Kidney function
serum creatinine level ≤ 1.5 × upper limit of normal (ULN)
Liver function
aspartate aminotransferase (AST) concentration / alanine aminotransferase (ALT) concentration ≤ 2.5 × ULN，total serum bilirubin concentration ≤ 1.5 × ULN
Hepatic function and renal function: serum creatinine level ≤ 1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) concentration / alanine aminotransferase (ALT) concentration ≤ 2.5 × ULN，total serum bilirubin concentration ≤ 1.5 × ULN. Blood routine: neutrophil count ≥ 1.5*10^9 / L, platelet count ≥ 100*10^9 / L, hemoglobin concentration ≥ 90 g / L (without transfusion).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04790305 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received neoadjuvant chemotherapy.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify